Molecular Biomarkers of Glioma

QR Code

Molecular Biomarkers of Glioma

In this review, we discuss how mutations in glioma are associated with prognosis and treatment efficacy. A fascinating characteristic of glioma and all cancers is that while common growth and developmental pathways are altered, the characteristic mutations are distinct depending on the specific type...

Full description

Saved in:

Bibliographic Details
Main Authors:	Punsasi Rajakaruna, Stella Rios, Hana Elnahas, Ashley Villanueva, David Uribe, Sophia Leslie, Walaa A. Abbas, Larissa Barroso, Stephanie Oyervides, Michael Persans, Wendy Innis-Whitehouse, Megan Keniry
Format:	Article
Language:	English
Published:	MDPI AG 2025-05-01
Series:	Biomedicines
Subjects:	glioma glioblastoma IDH oligodendroglioma astrocytoma
Online Access:	https://www.mdpi.com/2227-9059/13/6/1298
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Diffuse gliomas: insights into clinical and histopathological features and survival rates from two centers in a middle-income country
by: Edgar G. Ordóñez-Rubiano, et al.
Published: (2025-07-01)

Vorasidenib for IDH-mutant grade 2 gliomas: clinical advances and future directions
by: Zhenjiang Pan, et al.
Published: (2025-06-01)

Isocitrate Dehydrogenase-Wildtype Glioma Adapts Toward Mutant Phenotypes and Enhanced Therapy Sensitivity Under D-2-Hydroxyglutarate Exposure
by: Geraldine Rocha, et al.
Published: (2025-06-01)

GENETIC BIOMARKERS OF GLIAL BRAIN TUMORS: IDH1 AND IDH2 MUTATIONS
by: M. Yu. Prokudin, et al.
Published: (2020-09-01)

Intratumor morphologic and molecular genetic heterogeneity in astrocytomas of different grade of malignancy in the material from the first operation
by: D. E. Matsko, et al.
Published: (2022-01-01)

Role of Amide Proton Transfer Weighted MRI in Predicting MGMTp Methylation Status, p53-Status, Ki-67 Index, IDH-Status, and ATRX Expression in WHO Grade 4 High Grade Glioma
by: Faris Durmo, et al.
Published: (2025-05-01)

Isocitrate dehydrogenase 1 and 2 genes mutations and MGMT methylation in gliomas
by: D. V. Tabakov, et al.
Published: (2017-04-01)

Candidate gene mutations of patients with astrocytoma who present with seizures: evidence from whole exome sequencing
by: Kanitpong Phabphal, et al.
Published: (2025-07-01)

Immunohistochemical analysis of IDH1, ATRX, p53, and Ki-67 in glioblastoma and diffuse infiltrative glioma: Therapeutic and prognostic correlation
by: Hasbay Bermal, et al.
Published: (2025-01-01)

Natural Compounds That Target Glioma Stem Cells
by: Mariia Yaroshenko, et al.
Published: (2025-06-01)

Molecular characteristics of anaplastic astrocytomas and isolation of molecular subgroups of their IDH1 mutant forms using in silico analysis
by: P. V. Nikitin, et al.
Published: (2020-10-01)

Analysis of cerebrospinal fluid tumor-derived DNA to obviate biopsy of IDH-mutant brainstem glioma in an adult
by: Michael Youssef, et al.
Published: (2025-09-01)

Intra-tumoral molecular heterogeneity of grade 3 astrocytomas and oligodendrogliomas and its significance in disease prognosis
by: P. V. Nikitin, et al.
Published: (2023-12-01)

An Analysis for IDH‐Mutant Grade 4 Astrocytoma Based on WHO CNS 5: Implication of Clinical Practice
by: Xianxin Qiu, et al.
Published: (2025-07-01)

The mechanism of development of post-traumatic gliomas
by: I. F. Gareev, et al.
Published: (2021-12-01)

Experience in the use of dendritic vaccines in the treatment of patients with recurrent gliomas
by: M. Yu. Rykov, et al.
Published: (2022-12-01)

A multitask framework based on CA-EfficientNetV2 for the prediction of glioma molecular biomarkers
by: Qian Xu, et al.
Published: (2025-07-01)

Radiomics and Radiogenomics in Differentiating Progression, Pseudoprogression, and Radiation Necrosis in Gliomas
by: Sohil Reddy, et al.
Published: (2025-07-01)

Features of epileptiform activity in patients with diagnosed glioblastoma: from genetic and biochemical mechanisms to clinical aspects
by: E. E. Tyagunova, et al.
Published: (2022-12-01)

Dissecting the Immunological Microenvironment of Glioma Based on IDH Status: Implications for Immunotherapy
by: Miyu Kikuchi, et al.
Published: (2025-07-01)

CHANGES IN THE MGMT GENE EXPRESSION IN PATIENTS WITH PRIMARY GLIOBLASTOMA AFTER RELAPSE. INFLUENCE OF CLINICAL CHARACTERISTICS AND MGMT EXPRESSION ON SURVIVAL OF PATIENTS
by: M. V. Matsko, et al.
Published: (2021-06-01)

Matrix Metalloproteinases in Glioma: Drivers of Invasion and Therapeutic Targets
by: Ella E. Aitchison, et al.
Published: (2025-04-01)

PHOTODYNAMIC THERAPY AND SPECIFIC ANTITUMOR IMMUNE THERAPY IN THE STRUCTURE OF INTEGRATED TREATMENT OF PATIENTS WITH MALIGNANT ASTROCYTIC SUPRATENTORIAL TUMORS. LONG-TERM TREATMENT RESULTS
by: V. E. Olyushin, et al.
Published: (2014-12-01)

Temozolomide-based radio-chemotherapy for newly diagnosed pediatric high-grade gliomas (HIT-HGG-2007): A prospective, multicenter, single-arm, phase II trial
by: Michael Karremann, et al.
Published: (2025-12-01)

COMBINED CHEMOTHERAPY INCLUDING PROCARBAZINE (NATULAN) IN THE TREATMENT OF ANAPLASTIC OLIGODENDROGLIOMAS
by: D. R. Naskhletashvili, et al.
Published: (2015-04-01)

Artificial Intelligent‐Enhanced Metabolite Profiling for Intraoperative IDH1 Genotyping in Glioma Using an Orthogonally Responsive SERS Probe
by: Hang Yin, et al.
Published: (2025-07-01)

Predicting IDH and 1p/19q molecular status of gliomas with multi-b values DWI
by: Shanshan Zhao, et al.
Published: (2025-07-01)

Immunotherapy of malignant gliomas: a modern view on the problem
by: А. А. Pichugin, et al.
Published: (2024-12-01)

The Adverse Effects and Use of Bevacizumab in Patients with Glioblastoma: A Systematic Review and Meta-Analysis
by: Alejandro Bruna-Mejías, et al.
Published: (2025-05-01)

IDH1 Mutation Impacts DNA Repair Through ALKBH2 Rendering Glioblastoma Cells Sensitive to Artesunate
by: Olivier Switzeny, et al.
Published: (2025-06-01)

Diffuse midline glioma of the brainstem: genetic features, complications and treatment prospects
by: A. M. Kryanev, et al.
Published: (2024-06-01)

Study of interaction between extracellular matrix proteins and receptors of CD133+ stem cells and CD133– differentiated glioma cells
by: V. E. Shevchenko, et al.
Published: (2019-04-01)

Symptomatic Epileptic Seizures in Patients with Brain Gliomas
by: D. I. Abzalova, et al.
Published: (2021-11-01)

MORPHOLOGIC AND MOLECULAR FEATURES OF PRIMARY GLIOBLASTOMA IN PATIENTS SURVIVING MORE THAN 3 YEARS
by: M. V. Matsko, et al.
Published: (2019-06-01)

Regulatory role of circular RNAs in the development of therapeutic resistance in the glioma: A double-edged sword
by: Negin Masoomabadi, et al.
Published: (2025-01-01)

Integrated 4D label-free proteome and SUMOylated proteome in glioma uncover novel pathological mechanisms and pave the way for precision therapy
by: Jiazheng Wang, et al.
Published: (2025-08-01)

ONCOLYTIC VIROTHERAPY IN GLIOBLASTOMA TREATMENT: PROGRESS AND CHALLENGES IN CLINICAL RESEARCH (LITERATURE REVIEW)
by: O. I. Kit, et al.
Published: (2020-12-01)

Promises of targeted therapy for low grade gliomas in children
by: E. F. Valiakhmetova, et al.
Published: (2019-07-01)

Emerging Chemotherapy Targets: Insights from Advances in Glioma Treatment
by: Rogina Rezk, et al.
Published: (2025-06-01)

Efferential methods in complex treatment in patients with malignant cerebral neoplasms
by: R. Yu. Seliverstov, et al.
Published: (2009-02-01)